Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.6K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

710
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
710
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.6K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lower plasma resolvin D1 level and greater sputum eosinophilia characterize a cluster of severe asthma patients.

Respiratory research·2026
Same author

Understanding firefighter qualification under race-neutral spirometry and evolving National Fire Protection Association guidelines.

American journal of respiratory and critical care medicine·2026
Same author

Exacerbations and Decreased Lung Function Predict Nebulizer Use and Uptake in COPD and Tobacco Exposed Persons With Preserved Spirometry

Chronic obstructive pulmonary diseases (Miami, Fla.)·2026
Same author

Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways.

American journal of respiratory and critical care medicine·2026
Same author

Disease modification and progression in pre-chronic obstructive pulmonary disease: an official American Thoracic Society workshop report.

Annals of the American Thoracic Society·2026
Same author

A Quantitative Lung Mucin Score to Identify Chronic Bronchitis.

NEJM evidence·2026

Related Experiment Video

Updated: Mar 18, 2026

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.8K

Biomarkers in Severe Asthma.

Xiao Chloe Wan1, Prescott G Woodruff1

  • 1Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, 513 Parnassus Avenue, HSE 1305, San Francisco, CA 94143-0130, USA.

Immunology and Allergy Clinics of North America
|July 13, 2016
PubMed
Summary

Biomarkers are crucial for understanding severe asthma. Further research into non-type 2 inflammation biomarkers is essential for developing new treatments and management strategies.

Keywords:
BiomarkerEndotypeEosinophilExhaled nitric oxidePeriostinSevere asthma

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.5K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

28.9K

Related Experiment Videos

Last Updated: Mar 18, 2026

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.8K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.5K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

28.9K

Area of Science:

  • * Respiratory Medicine
  • * Immunology
  • * Biomarker Discovery

Background:

  • * Biomarkers have significantly advanced severe asthma research, particularly in understanding type 2 inflammation.
  • * Type 2 inflammation biomarkers are key for disease endotyping and guiding biological therapies.
  • * A knowledge gap exists regarding non-type 2 inflammatory mechanisms in severe asthma.

Purpose of the Study:

  • * To highlight the critical role of biomarkers in severe asthma research.
  • * To emphasize the need for investigating non-type 2 inflammatory pathways.
  • * To underscore the potential of biomarkers in uncovering underlying biology for future therapeutic development.

Main Methods:

  • * Review of existing literature on asthma biomarkers.
  • * Analysis of the impact of type 2 inflammation biomarkers.
  • * Discussion of the challenges and opportunities in non-type 2 inflammation research.

Main Results:

  • * Type 2 inflammation biomarkers have been instrumental in severe asthma endotyping and treatment.
  • * The lack of understanding of non-type 2 inflammation is a growing impediment to therapeutic advancement.
  • * Biomarkers offer a pathway to investigate non-type 2 mechanisms in patient studies.

Conclusions:

  • * Continued biomarker research is vital for addressing unmet needs in severe asthma.
  • * Focusing on non-type 2 inflammation is the next frontier for severe asthma treatment development.
  • * Biomarkers will be essential tools for elucidating complex inflammatory pathways in severe asthma.